drugset

drugset / Trial / NCT00560235

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

NCT00560235 ↗

Phase 1/2 Completed 138 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors

Timeline

Start: 2008-03
Primary completion: 2010-03
Completion: 2012-10

Publications

Juergens H, Daw NC, Geoerger B, Ferrari S, Villarroel M, Aerts I, Whelan J, Dirksen U, Hixon ML, Yin D, Wang T, Green S, Paccagnella L, Gualberto A. Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol. 2011 Dec 1;29(34):4534-40. doi: 10.1200/JCO.2010.33.0670. Epub 2011 Oct 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Figitumumab	Monoclonal antibody	20 mg/kg	Intravenous
Subject	Figitumumab	Monoclonal antibody	30 mg/kg	Intravenous

Indications